Headlines

Pfizer and BioNTech begin early research on combination vaccine to protect against COVID-19 and flu

Pfizer and BioNTech begin early research on combination vaccine to protect against COVID-19 and flu

Biopharmaceutical company Pfizer Inc. is teaming up with Germany’s BioNTech SE to conduct an early-stage study to analyze a vaccination that can protect individuals against COVID-19 and influenza.

The companies announced Thursday that the single-dose vaccine candidate will do Omicron booster shot and an mRNA flu vaccine manufactured by Pfizer.

The study will assess whether the injection is tolerable, as well as safer, for human patients or has the ability to produce an immune system response. One hundred and eighty people from the USA between the ages of 18 and 64 will be used in the study.

“The flexibility and speed of production of mRNA technology has shown that it is well suited to other respiratory diseases,” Pfizer Chief Scientific Officer Annaliese Anderson said in a statement. “Pfizer is deeply proud of our continued work to explore its potential to protect against influenza and COVID-19 in a single combination vaccine, which we think could simplify the practice of immunization against these two respiratory pathogens, potentially leading to better vaccine uptake for both diseases .”

RECOVERY OF COVID-19 SYMPTOMS AFTER PAXLOVID MAY BE DUE TO AN IMMUNE SYSTEM RESPONSE

Pfizer is working with BioNTech to develop a combination vaccine that can protect against influenza and COVID-19.

Pfizer is working with BioNTech to develop a combination vaccine that can protect against influenza and COVID-19.
(AP Photo/Steven Senne)

“Even with existing seasonal flu vaccines, the burden of this virus is severe worldwide, causing thousands of deaths and hospitalizations each year. This is an exciting step in our ongoing journey with BioNTech as we work together to transform the prevention of infectious diseases around the world.” , Anderson added.

The first participant to receive a dose received the combination vaccine earlier this week. Meanwhile, rival drugmaker Moderna Inc. is working with Novavax to create a vaccine capable of fighting both COVID-19 and influenza.

Although it is USA COVID-19 rate is declining, companies are still looking to develop different protections against variants of the infectious disease.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP



#Pfizer #BioNTech #early #research #combination #vaccine #protect #COVID19 #flu

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button